About Inovio Pharmaceuticals (NASDAQ:INO)
Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:INO
- CUSIP: N/A
- Web: www.inovio.com
Capitalization:- Market Cap: $563.92 million
- Outstanding Shares: 90,227,000
Average Prices:- 50 Day Moving Avg: $6.22
- 200 Day Moving Avg: $6.64
- 52 Week Range: $5.28 - $9.86
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.15
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $51.84 million
- Price / Sales: 10.84
- Book Value: $1.59 per share
- Price / Book: 3.92
Profitability:- EBITDA: ($70,600,000.00)
- Net Margins: -153.46%
- Return on Equity: -63.67%
- Return on Assets: -46.77%
Debt:- Current Ratio: 3.90%
- Quick Ratio: 3.90%
Misc:- Average Volume: 1.57 million shs.
- Beta: 2.76
- Short Ratio: 4.01
Frequently Asked Questions for Inovio Pharmaceuticals (NASDAQ:INO)
What is Inovio Pharmaceuticals' stock symbol?
Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."
When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?
Inovio Pharmaceuticals's stock reverse split on the morning of Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.
How were Inovio Pharmaceuticals' earnings last quarter?
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) issued its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.08. The firm earned $20.41 million during the quarter, compared to analyst estimates of $16.29 million. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. Inovio Pharmaceuticals's revenue was up 229.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.26) EPS. View Inovio Pharmaceuticals' Earnings History.
Where is Inovio Pharmaceuticals' stock going? Where will Inovio Pharmaceuticals' stock price be in 2017?
10 equities research analysts have issued twelve-month price targets for Inovio Pharmaceuticals' shares. Their predictions range from $10.00 to $40.00. On average, they expect Inovio Pharmaceuticals' stock price to reach $20.20 in the next twelve months. View Analyst Ratings for Inovio Pharmaceuticals.
What are analysts saying about Inovio Pharmaceuticals stock?
Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Inovio has a collaboration agreement with several companies and institutes like big pharma companies Roche, AstraZeneca, and the University of Pennsylvania, which not only lend it their expertise but also provide the required funding for development of its pipeline candidates. Also, the company’s progress with its pipeline is impressive. Nonetheless, the company’s targeted cervical cancer market holds huge untapped potential. The initiation of phase III program on its lead pipeline candidate, VGX-3100, for treatment of cervical dysplasia is encouraging. However, due to the early/mid-stage nature of Inovio’s pipeline, the company is highly dependent on VGX-3100, which is concerning. Shares of the company have underperformed the industry so far this year." (10/10/2017)
- 2. Maxim Group analysts commented, "Inovio announced a collaboration with Roche (RHHBY – $34.10 – NR) to evaluate their DNA-based immunotherapies INO-5401 (multiple cancer antigens) and INO-9012 (IL-12 immune stimulator) with Tecentriq (PD-L1 checkpoint) in advanced bladder cancer." (6/1/2017)
Who are some of Inovio Pharmaceuticals' key competitors?
Some companies that are related to Inovio Pharmaceuticals include Arena Pharmaceuticals (ARNA), Momenta Pharmaceuticals (MNTA), Intellia Therapeutics (NTLA), Editas Medicine (EDIT), Cellectis S.A. (CLLS), Albany Molecular Research (AMRI), Enanta Pharmaceuticals (ENTA), Heron Therapeutics (HRTX), Abeona Therapeutics (ABEO), BeyondSpring (BYSI), Crispr Theraptc (CRSP), ANI Pharmaceuticals (ANIP), AC Immune SA (ACIU), ImmunoGen (IMGN), WAVE Life Sciences (WVE), Voyager Therapeutics (VYGR), Celyad SA (CYAD) and Mesoblast Limited (MESO).
Who are Inovio Pharmaceuticals' key executives?
Inovio Pharmaceuticals' management team includes the folowing people:
- Jong Joseph Kim Ph.D., President, Chief Executive Officer, Director
- Peter D. Kies, Chief Financial Officer
- Niranjan Y. Sardesai Ph.D., Chief Operating Officer
- Mark L. Bagarazzi M.D., Chief Medical Officer
- Avtar S. Dhillon M.D., Non-Executive Chairman of the Board
- George W. Bickerstaff III, Director
- David B. Weiner, Director
- Simon X. Benito, Independent Director
- Angel Cabrera Ph.D., Independent Director
How do I buy Inovio Pharmaceuticals stock?
Shares of Inovio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Inovio Pharmaceuticals' stock price today?
One share of Inovio Pharmaceuticals stock can currently be purchased for approximately $6.23.
MarketBeat Community Rating for Inovio Pharmaceuticals (NASDAQ INO)MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Inovio Pharmaceuticals (NASDAQ:INO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 8 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.80) |
| Consensus Price Target: | $20.20 (224.24% upside) |
Consensus Price Target History for Inovio Pharmaceuticals (NASDAQ:INO)
Analysts' Ratings History for Inovio Pharmaceuticals (NASDAQ:INO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/18/2017 | Royal Bank Of Canada | Initiated Coverage | Outperform -> Outperform | $11.00 | N/A |  |
| 10/17/2017 | HC Wainwright | Set Price Target | Buy | $13.00 | N/A | |
| 10/6/2017 | Citigroup Inc. | Initiated Coverage | Buy | $10.00 | N/A | |
| 9/12/2017 | Maxim Group | Reiterated Rating | Buy | $12.00 | Low | |
| 7/18/2017 | Aegis | Reiterated Rating | Buy | $14.00 | Low | |
| 6/8/2017 | Piper Jaffray Companies | Upgrade | Neutral -> Overweight | $14.00 | Medium | |
| 5/25/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $11.00 | High | |
| 5/1/2017 | Nomura | Reiterated Rating | Buy | $40.00 | Low | |
| 5/1/2017 | Jefferies Group LLC | Reiterated Rating | Neutral | $38.00 | Low | |
| 5/1/2017 | BNP Paribas | Reiterated Rating | Neutral | $39.00 | Low | |
| 10/4/2016 | Brean Capital | Initiated Coverage | Buy | $18.00 | N/A | |
| 6/21/2016 | Rodman & Renshaw | Reiterated Rating | Buy | $17.00 | N/A | |
(Data available from 10/21/2015 forward)
Earnings History for Inovio Pharmaceuticals (NASDAQ:INO)Earnings History by Quarter for Inovio Pharmaceuticals (NASDAQ INO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/8/2017 | Q2 17 | ($0.21) | ($0.13) | $16.29 million | $20.41 million | View | Listen | |
| 5/10/2017 | Q1 2017 | ($0.31) | ($0.31) | $5.83 million | $10.40 million | View | N/A | |
| 3/15/2017 | Q4 2016 | ($0.29) | ($0.35) | $5.21 million | $8.50 million | View | N/A | |
| 11/9/2016 | Q316 | ($0.26) | ($0.28) | $5.16 million | $12.54 million | View | Listen | |
| 8/8/2016 | Q2 | ($0.21) | ($0.26) | $4.95 million | $6.20 million | View | N/A | |
| 5/9/2016 | Q1 | ($0.14) | ($0.11) | $4.75 million | $8.10 million | View | N/A | |
| 3/14/2016 | Q4 | ($0.20) | ($0.25) | $6.96 million | $5.94 million | View | Listen | |
| 11/9/2015 | Q3 | $0.04 | $0.07 | $1.84 million | $24.18 million | View | N/A | |
| 8/10/2015 | Q215 | ($0.13) | ($0.10) | $5.52 million | $5.30 million | View | Listen | |
| 5/11/2015 | Q1 | ($0.11) | ($0.18) | $7.04 million | $5.20 million | View | Listen | |
| 3/16/2015 | Q414 | ($0.10) | ($0.12) | $5.24 million | $2.50 million | View | N/A | |
| 11/10/2014 | Q314 | ($0.11) | ($0.12) | $5.60 million | $1.80 million | View | N/A | |
| 8/11/2014 | Q214 | ($0.17) | ($0.19) | $1.80 million | $3.80 million | View | N/A | |
| 5/12/2014 | Q114 | ($0.04) | ($0.05) | $1.41 million | $2.40 million | View | N/A | |
| 3/17/2014 | Q413 | ($0.03) | ($0.04) | $1.36 million | $1.70 million | View | N/A | |
| 11/11/2013 | Q3 | ($0.02) | ($0.16) | $2.99 million | $9.50 million | View | Listen | |
| 11/7/2012 | Q312 | ($0.05) | ($0.05) | $2.07 million | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Inovio Pharmaceuticals (NASDAQ:INO)Current Year EPS Consensus Estimate: $-0.88 EPS
Next Year EPS Consensus Estimate: $-1.21 EPS
Dividend History for Inovio Pharmaceuticals (NASDAQ:INO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Inovio Pharmaceuticals (NASDAQ:INO)Insider Ownership Percentage: 10.60%
Institutional Ownership Percentage: 24.83%
Insider Trades by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/25/2017 | David B Weiner | Director | Sell | 8,000 | $8.00 | $64,000.00 | |
| 3/31/2017 | Jong Joseph Kim | CEO | Sell | 147,180 | $6.54 | $962,557.20 | |
| 3/27/2017 | Morton Collins | Director | Buy | 21,300 | $6.25 | $133,125.00 | |
| 8/29/2016 | Niranjan Sardesai | COO | Sell | 21,800 | $9.30 | $202,740.00 | |
| 6/28/2016 | Morton Collins | Director | Buy | 10,000 | $9.13 | $91,300.00 | |
| 5/18/2016 | Simon X Benito | Director | Sell | 6,250 | $10.37 | $64,812.50 | |
| 4/15/2016 | Morton Collins | Director | Buy | 68,400 | $9.52 | $651,168.00 | |
| 9/30/2015 | Niranjan Sardesai | COO | Buy | 4,000 | $5.50 | $22,000.00 | |
| 8/14/2015 | Simon X Benito | Director | Buy | 6,000 | $7.21 | $43,260.00 | |
| 4/13/2015 | Angel Cabrera | Director | Buy | 8,000 | $9.53 | $76,240.00 | |
| 10/9/2014 | Peter Kies | CFO | Buy | 3,960 | $10.10 | $39,996.00 | |
| 8/21/2014 | Morton Collins | Director | Buy | 8,000 | $10.01 | $80,080.00 | |
| 8/20/2014 | Morton Collins | Director | Buy | 40,600 | $9.74 | $395,444.00 | |
| 8/12/2014 | Jong Joseph Kim | CEO | Buy | 250,000 | $9.06 | $2,265,000.00 | |
| 8/12/2014 | Niranjan Sardesai | COO | Buy | 2,550 | $8.70 | $22,185.00 | |
| 4/15/2014 | Jong Joseph Kim | CEO | Buy | 25,000 | $2.25 | $56,250.00 | |
| 11/13/2013 | Morton Collins | Director | Buy | 254,500 | $1.82 | $463,190.00 | |
| 4/16/2013 | Mark Bagarazzi | Insider | Buy | 60,000 | $0.56 | $33,600.00 | |
| 4/2/2013 | Jong Joseph Kim | CEO | Buy | 90,000 | $0.50 | $45,000.00 | |
| 3/22/2013 | Angel Cabrera | Director | Buy | 40,000 | $0.54 | $21,600.00 | |
| 3/20/2013 | Jong Joseph Kim | CEO | Buy | 60,000 | $0.53 | $31,800.00 | |
| 3/20/2013 | Niranjan Sardesai | COO | Buy | 25,000 | $0.53 | $13,250.00 | |
| 1/15/2013 | Morton Collins | Director | Buy | 100,000 | $0.67 | $67,000.00 | |
| 11/14/2012 | Austin W & Greenhouse Da Marxe | Major Shareholder | Sell | 622,550 | $0.53 | $329,951.50 | |
| 8/15/2012 | Angel Cabrera | Director | Buy | 75,000 | $0.59 | $44,250.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Inovio Pharmaceuticals (NASDAQ:INO)
Latest Headlines for Inovio Pharmaceuticals (NASDAQ:INO)
| Source: |
|
| Date | Headline |
|---|
 | Corporate News Blog - Inovio Initiates Phase-1b/2 Cancer Efficacy Trial
finance.yahoo.com - October 19 at 5:31 AM |
 | Inovio Pharmaceuticals, Inc. (INO) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 18 at 11:02 PM |
 | Inovio Initiates Bladder Cancer Study With Roche's Tecentriq - Nasdaq - Nasdaq
www.nasdaq.com - October 18 at 1:41 AM |
| Inovio Initiates Bladder Cancer Study With Roche's Tecentriq
finance.yahoo.com - October 18 at 1:41 AM |
 | Inovio Pharmaceuticals Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T-cell Immunotherapy with a PD-L1 ... - GlobeNewswire (press release)
globenewswire.com - October 16 at 3:39 PM |
| Inovio Pharmaceuticals, Inc. (INO) Cut to "Sell" at BidaskClub
www.americanbankingnews.com - October 14 at 8:22 AM |
| -$0.22 EPS Expected for Inovio Pharmaceuticals, Inc. (INO) This Quarter
www.americanbankingnews.com - October 12 at 4:26 AM |
| ETFs with exposure to Inovio Pharmaceuticals, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 7:56 PM |
| Inovio Pharmaceuticals, Inc. (INO) Now Covered by Analysts at Citigroup Inc.
www.americanbankingnews.com - October 7 at 6:06 PM |
 | Inovio Pharma (INO) Says Positive Zika Vaccine Clinical Study Data Published in NEJM - StreetInsider.com
www.streetinsider.com - October 7 at 4:38 AM |
| Inovio Pharmaceuticals, Inc. :INO-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 6 at 11:34 PM |
| Inovio Pharmaceuticals, Inc. (INO) PT Set at $13.00 by HC Wainwright
www.americanbankingnews.com - October 6 at 9:12 AM |
 | A Zika Vaccine Shows Signs of Success in an Early Human Trial - Fortune
fortune.com - October 6 at 8:43 AM |
| Brainstorm Health: Zika Vaccine, Sanofi/Regeneron Catch a Break, Does Obamacare Still Exist
fortune.com - October 6 at 12:24 AM |
 | BRIEF-Inovio Pharmaceuticals reports positive results from phase 1 trial of zika virus vaccine
www.reuters.com - October 6 at 12:24 AM |
| Inovio Rises On Phase 1 Data for Zika Vaccine -- Biotech Movers
finance.yahoo.com - October 6 at 12:23 AM |
| Zika vaccine shows promise in early human trial - Reuters
www.reuters.com - October 5 at 8:58 AM |
| Inovio's Positive Zika Vaccine Clinical Study Data Published in New England Journal of Medicine - GlobeNewswire (press release)
globenewswire.com - October 5 at 8:58 AM |
| Inovio’s Positive Zika Vaccine Clinical Study Data Published in New England Journal of Medicine
finance.yahoo.com - October 5 at 8:58 AM |
 | GLOBAL DNA VACCINE MARKET FORECAST 2017-2025
www.prnewswire.com - October 4 at 5:37 PM |
| Zika vaccine shows promise in early human trial
finance.yahoo.com - October 4 at 5:37 PM |
| Inovio Pharmaceuticals, Inc. (INO) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 23 at 8:50 PM |
| Inovio Pharmaceuticals, Inc. (INO) Expected to Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - September 23 at 2:26 PM |
| Inovio Pharmaceuticals' (INO) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - September 22 at 5:44 PM |
| ETF Preview: ETFs, Futures Mixed Following Weekly Jobless Claims, Philly Fed Manufacturing Data
www.nasdaq.com - September 21 at 4:07 PM |
| Inovio dMAb™ Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection ... - GlobeNewswire (press release)
www.globenewswire.com - September 21 at 9:29 AM |
| Inovio dMAb™ Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection In Preclinical Studies
finance.yahoo.com - September 21 at 9:29 AM |
| Inovio shares jump 5% premarket after two peer-reviewed paper support its research
finance.yahoo.com - September 21 at 9:29 AM |
| Inovio Pharma (INO) and Its Partners Begin Phase 1/2a Trial to ... - StreetInsider.com
www.streetinsider.com - September 20 at 4:21 PM |
| Inovio Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : INO-US : September 20, 2017
finance.yahoo.com - September 20 at 4:21 PM |
| BRIEF-Inovio and partners initiate Phase 1/2A clinical trial to further advance its vaccine against deadly MERS infection
www.reuters.com - September 18 at 7:23 PM |
| Inovio and Partners Initiate Phase 1/2a Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection
finance.yahoo.com - September 18 at 7:23 PM |
| Inovio Pharmaceuticals, Inc. (INO) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - September 17 at 10:58 PM |
| Inovio Pharmaceuticals, Inc. (INO) Stock Rating Reaffirmed by Maxim Group
www.americanbankingnews.com - September 17 at 10:58 PM |
 | Inovio Pharmaceuticals (INO) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 3:13 AM |
| INO-5150 generated antigen specific T cell immune responses in a phase 1b clinical study
globenewswire.com - September 11 at 8:38 PM |
 | Inovio Pharma Reports Promising Phase 1b Clinical Trial Data Of INO-5150
www.rttnews.com - September 11 at 8:38 PM |
| Inovio’s Cancer Immunotherapy (INO-5150) Slowed PSA Rise and Significantly Increased PSA Doubling Times In Patients with Recurrent Prostate Cancer
finance.yahoo.com - September 11 at 8:38 PM |
| Inovio Pharmaceuticals, Inc. (INO) Earns Buy Rating from Analysts at Citigroup Inc.
www.americanbankingnews.com - September 10 at 8:16 PM |
| Surging Earnings Estimates Signal Good News for Inovio (INO)
finance.yahoo.com - September 7 at 8:11 PM |
| Is Inovio Pharmaceuticals Stock Poised for a Rebound?
finance.yahoo.com - September 6 at 6:25 AM |
| $14.04 Million in Sales Expected for Inovio Pharmaceuticals, Inc. (INO) This Quarter
www.americanbankingnews.com - September 6 at 3:16 AM |
 | Is Inovio Pharmaceuticals Stock Poised for a Rebound? - Motley Fool
www.fool.com - August 30 at 2:17 AM |
| Inovio Pharmaceuticals, Inc. (INO) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 29 at 9:14 PM |
| Financial Review: Inovio Pharmaceuticals (INO) and Abeona Therapeutics (ABEO)
www.americanbankingnews.com - August 24 at 10:26 PM |
| Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences
finance.yahoo.com - August 24 at 7:59 AM |
 | Ironwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers - TheStreet.com
www.thestreet.com - August 22 at 12:07 AM |
| Inovio Pharmaceuticals, Inc. (INO) Expected to Post Quarterly Sales of $14.04 Million
www.americanbankingnews.com - August 19 at 1:34 PM |
| Inovio Pharmaceuticals, Inc. (INO) Short Interest Update
www.americanbankingnews.com - August 12 at 1:44 AM |
| Inovio (INO) Q2 Loss Narrower Than Expected, Revenues Beat
finance.yahoo.com - August 11 at 11:24 PM |
Inovio Pharmaceuticals (INO) Chart for Saturday, October, 21, 2017
